Integra LifeSciences Holdings Corporation (IART)
Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up
IART delivers better-than-expected earnings in the fourth quarter of 2024.
Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript
Integra (IART) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) Surpasses Q4 Earnings Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.89 per share a year ago.
IART vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Is Integra LifeSciences (IART) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
IART or PEN: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Is Integra LifeSciences (IART) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Hold IART Stock in Your Portfolio Now
Integra's growth within its Tissue Technologies business segment bolsters investors' confidence in the stock.
Reasons to Retain IART Stock in Your Portfolio for Now
Integra's strong growth in the CSS business segment bolsters investors' confidence in the stock. Meanwhile, the weak liquidity position adds to the worry.
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs.
Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure
IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter.
